Cellectar Biosciences, INC Schedule 13G passive stakes

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 9.99% of Cellectar Biosciences Inc.'s Class A Common Stock, primarily through exercisable warrants.

Balyasny Asset Management L.P. and affiliated entities have reported a beneficial ownership of 9.99% in Cellectar Biosciences, Inc., following adjustments related to warrant exercises and ownership limitations.

Empery Asset Management, LP and Ryan M. Lane have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of Cellectar Biosciences, Inc. common stock, including shares issuable upon warrant exercise.

Janus Henderson Group plc has filed a Schedule 13G reporting beneficial ownership of 9.99% of Cellectar Biosciences, Inc. common stock.

Stonepine Capital Management has reported a 9.9% beneficial ownership stake in Cellectar Biosciences following recent equity and warrant issuances.

Rosalind Advisors and affiliated funds disclose a 5.5% beneficial ownership in Cellectar Biosciences, Inc., factoring in conversion limitations.

Hexstone Capital LLC and Brendan O'Neil have filed an amendment indicating they are no longer beneficial owners of more than 5% of Cellectar Biosciences, Inc. common stock.

Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have jointly reported a 6.08% beneficial ownership stake in Cellectar Biosciences, Inc., totaling 200,000 common shares.

ADAR1 Capital Management and related entities disclose a passive 0.1% beneficial ownership stake in Cellectar Biosciences, Inc.

Laurence W. Lytton has disclosed a 1.6% beneficial ownership stake in Cellectar Biosciences, Inc., primarily through warrants.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 0.06% beneficial ownership stake in Cellectar Biosciences, Inc. as of June 30, 2025.

Hexstone Capital LLC and Brendan O'Neil have reported a 5.6% beneficial ownership stake in Cellectar Biosciences, Inc., holding 150,000 shares.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 4.99% in Cellectar Biosciences, Inc. common stock as of July 8, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 5.73% in Cellectar Biosciences, Inc. as of December 31, 2024.

Laurence W. Lytton has filed an amended Schedule 13G, disclosing an 8.8% beneficial ownership stake in Cellectar Biosciences, Inc., primarily through common stock and warrants.

Rosalind Advisors, Inc. and its affiliated funds, Rosalind Master Fund L.P. and Rosalind Opportunities Fund I L.P., along with their principals, have filed an amended Schedule 13G, reaffirming their passive beneficial ownership of 9.9% of Cellectar Biosciences, Inc.'s common stock, subject to a 9.99% ownership blocker.

AIGH Capital Management and Orin Hirschman jointly filed a Schedule 13G, disclosing a 4.9% beneficial ownership stake in Cellectar Biosciences, Inc. as of December 31, 2024.